Dynavax Technologies Corporation
9 News & Press Releases found

Dynavax Technologies Corporation news

Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today announced that 

May. 25, 2022

Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today announced that 

May. 16, 2022

Dynavax Technologies Corporation (Nasdaq: DVAX) today reported that it has granted restricted stock units (RSUs) covering an aggregate of 16,000 shares of Dynavax common stock as inducements to 2 newly-hired employees in connection with commencement of employme

Mar. 3, 2022

Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing vaccines, today announced that 

Feb. 23, 2022

Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial stage biopharmaceutical company focused on developing and commercializing innovative vaccines, will report fourth quarter and full year 2021 financial results on Monday, February 28, 2022, after the 

Feb. 16, 2022

Dynavax Technologies Corporation (Nasdaq: DVAX) today reported that it has granted nonstatutory stock options to purchase an aggregate of 105,000 shares of Dynavax common stock and restricted stock units (RSUs) covering an aggregate of 73,250 shares of Dynavax

Feb. 2, 2022
  • Dynavax expects year over year revenue growth for HEPLISAV-B and CpG 1018 adjuvant to drive continued profitability in 2022
  • Strong financial position supports investment in long-term growth drivers including pipeline expansion
  • Initiation of Phase 1 clinical trial of shingles vaccine candidate, adjuvanted with CpG 1018, with data expected year end 2022

Jan. 10, 2022

Dynavax Technologies Corporation (Nasdaq: DVAX) today reported that it has granted nonstatutory stock options to purchase an aggregate of 94,000 shares of Dynavax common stock and restricted stock units (RSUs) covering an aggregate of 2,500 shares of 

Jan. 7, 2022

Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing vaccines, today announced that 

Jan. 5, 2022